Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_870c6e68c09f6b820fc9b7fefe1a56fc |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-91 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-115 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0663 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-28 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0775 |
filingDate |
2018-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_885a8a8cac26e695c8128bc2704c3cfc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a7cccbf8f0cb87d9803db8972bbfc7c0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8fd0c726a178331b79d7fdba0f180003 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f7b79eb63745fc1765ea8ab6d7b02b4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6df331f362682ec4dc84855478b87348 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d20bd99a1e406fb80865a78d38a8f14 |
publicationDate |
2019-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
BE-1025935-A1 |
titleOfInvention |
METHOD FOR DIFFERENTIATING MESENCHYMAL STEM CELLS |
abstract |
The present invention relates to a method for obtaining CSM derived cells having improved transplantation properties from CSM, the method comprising a cell size reduction step, wherein said cell size reduction step is characterized by contacting CSM or cells derived from CSM in vitro or ex vivo with heparin or a derivative or analogue thereof at a concentration of at least 0.01 IU / ml. The invention further relates to a method for obtaining cells derived from mesenchymal stem cells from mesenchymal stem cells (MSCs) comprising contacting CSM in vitro or ex vivo with FGF-2, TGF-I3 and at least 0.01 IU / ml heparin or a derivative or analogue thereof. The invention further relates to cells and cell populations thus obtained, as well as additional products comprising them and uses thereof. |
priorityDate |
2017-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |